Cell Culture Becomes an Integral Part of Cell Line Development and Engineering

LONDON, December 5, 2012 /PRNewswire/ --

- Market demands to reduce manufacturing costs require better Cell culture processes

According to further research conducted for the annual 2013 Cell Line Development & Engineering conference in Vienna next February, major developments in cell culture systems have given biotech's and pharmaceutical companies more flexibility to scale up cells to a high manufacturing quality. Cell engineering tools have enabled the production of high-performing cell lines and this has only been possible through improvements in cell culture media.

To best accommodate for these new developments, Informa Life Sciences' have expanded the programme to cover the latest in cell line development strategies and improvements in cell culture systems. Speaker Alison Porter, Head of Cell Line Development in the Mammalian Cell Culture group at Fujifilm Diosynth Biotechnologies (FFDB) clarifies how '‘With cell line construction on the critical path for first in human studies, it is vital to have optimised the early stages of cell line development. This can improve the future success of a biotherapeutic, both in terms of having the 'best' cell line and meeting increasingly tight timelines.'’

Further feedback from over 50 industry professionals and academics also highlight additional trends such as high throughput screening of cell lines, Quality by Design applications, cell line development strategies for novel products, analytical tools for product evaluation and bioinformatics applications.

Informa's annual 2013 Cell Line Development & Engineering conference has been designed to address topics essential to improve product development and quality. Susanna Benaim Conference Producer at Informa Life Sciences explains "The event uncovers the essentials in micro-scale system application, CHO genome sequencing, cell line engineering and targeted integration. The conference brings together leading experts from protein engineering, cell biology, cell line development and bioprocess, from both the pharmaceutical industry and academia. Any company specialising in this area is encouraged not to miss out."

Background

Cell Line Development & Engineering 2013 will take place on the 11^th-15^th February 2013 at the NH Atlanta in Vienna, Austria. With a sold-out attendance in 2012 and a packed exhibition room, the 2013 conference is already receiving support from some of the leading names and companies in the industry including;

• Dr Sanjeev Gupta (Intas Pharma)
• Dr Otfried Kistner (Baxter Innovations)
• Dr Baisong Mei (Biogen Idec)
• Prof Dr Nicole Borth (BOKU)
• Dr Eric Becker (Boehringer Ingelheim)
• Prof Florian Wurum (ExcellGene)
• Dr Alison Potter (Fuji Film)
• Dr Marcos Arauzo-Bravo (Max Planck)
• Dr Martin Jordan (Merck Serono)
• Prof Alan Dickson (Uni. of Manchester)
• Prof David James (Uni. Of Sheffield)
• Prof Nicolas Mermod (Uni. Of Lausanne)

Delegates and exhibitors can apply by registering online. For more information on how to register or to download a copy of the programme, please visit http://www.informa-ls.com/celldev

Other Related Events include;

• BPI Europe 2013 / BioProcess International conference
• BioProduction conference

Contacts:
Susanna Benaim
Conference Producer
Susanna.benaim@informa.com

James Miguel
Sales Director
James.miguel@informa.com